Rhythm Pharmaceuticals, Inc. (RYTM) - Stock Analysis

Last updated: Sep 20, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Shares gained 28.5% through November 19 and closed near their recent peak; Q3 IMCIVREE revenue rose 29% sequentially, with launches and approvals supporting commercial momentum. Losses keep the trade high-risk.

Loading chart data...

Idea window: 11/20/2026 – 11/27/2026Sector: Healthcare

AI Analyst Overview

Last Price
$112.36
Market Cap
$7.79B
1D Return
-3.80%
YTD Return
+4.97%

Loading chart data...

Valuation Metrics

P/E
-38.7
P/B
38.5
P/S
27.8
EV/EBITDA
-45.0
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • High Gross Margins • Strong Liquidity Position • Ongoing Cash Burn RYTM combines strong 88% gross margins and ample liquidity with persistent losses, negative cash flow, and a valuation that appears high relative to its current revenue base.

LiquidityStrength
ValuationRisk

Price Behavior

4.0

Key Price Behavior Insights: • Lower highs • Oversold momentum • Key support Support Level: $96.77 Resistance Level: $99.00–$102.00, then $104.70–$105.40 RYTM remains bearish after a 10% decline over the last month, though oversold RSI near $96.77 support may spark a rebound; reclaiming $102 and then $105 is needed to improve the trend.

Bearish
Oversold

Sentiment & News

6.0

Key News Insights: • Japan Approval • Positive Trial Data • Insider Selling Rhythm's Japan approval and positive clinical data strengthen IMCIVREE's growth outlook, though CEO share sales and a stock decline may pressure near-term sentiment.

ClinicalProgress
InsiderSelling
AI

AI Summary

6.0
Neutral

RYTM's investment case has shifted from pipeline promise to proving that hypothalamic-obesity start forms convert into durable, reimbursed IMCIVREE revenue—an essential test because its ~30x-sales valuation already prices in strong execution across U.S. adoption, Japan, and Prader-Willi expansion. Investors should wait for repeatable paid-patient growth and improving cash burn before treating near-term momentum as a durable rerating opportunity.

CommercialGrowth
ValuationRisk
Reimbursement
AI summary updated 61 days ago

Description

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare, genetically driven forms of obesity. Its lead product candidate, IMCIVREE, is a melanocortin-4 receptor agonist being developed for several inherited obesity disorders including POMC, PCSK1 and LEPR deficiencies as well as Bardet-Biedl and AlstrĂśm syndromes; the company also has clinical-stage programs evaluating setmelanotide for additional monogenic and syndromic obesity indications. Rhythm maintains a research collaboration related to Bardet-Biedl syndrome, was founded in 2008, and is headquartered in Boston, Massachusetts.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Nov 20Nov 27RYTMRhythm Pharmaceuticals, Inc.
Shares gained 28.5% through November 19 and closed near their recent peak; Q3 IMCIVREE revenue rose 29% sequentially, with launches and approvals supporting commercial momentum. Losses keep the trade high-risk.
Active+0.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.